US5436233A - 4-aminoquinazoline derivatives - Google Patents

4-aminoquinazoline derivatives Download PDF

Info

Publication number
US5436233A
US5436233A US08/154,518 US15451893A US5436233A US 5436233 A US5436233 A US 5436233A US 15451893 A US15451893 A US 15451893A US 5436233 A US5436233 A US 5436233A
Authority
US
United States
Prior art keywords
quinazoline
amino
imidazolyl
alkyl
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/154,518
Other languages
English (en)
Inventor
Sung J. Lee
Yoshitaka Konishi
Orest T. Macina
Kigen Kondo
Dingwei T. Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Priority to US08/154,518 priority Critical patent/US5436233A/en
Assigned to ONO PHARMACEUTICAL CO., LTD. reassignment ONO PHARMACEUTICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LEE, SUNG JAI, MACINA, OREST TARAS, YU, DINGWEI TIM, KONDO, KIGEN, KONISHI, YOSHITAKA
Application granted granted Critical
Publication of US5436233A publication Critical patent/US5436233A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Definitions

  • the present invention relates to novel 4-aminoquinazoline derivatives. More particularly, this invention relates to:
  • Cyclic guanosine 3',5'-monophosphate (abbreviated as cGMP hereafter) was found in urine in rats by D. F. Ashman in 1963. Till now, it has been known that cGMP is distributed broadly in tissues of many animals including human beings. cGMP is biosynthesized from guanosine triphosphate (GTP) by the action of guanylate cyclase.
  • GTP guanosine triphosphate
  • cGMP has been experimentally confirmed to have various physiological activities. For example, cGMP induces the relaxation of heart muscle and of smooth muscle. Further, it is related to the formation of neuronal synapses, and it acts as a trigger of cell proliferation and it induces the proliferation of lymphocyte.
  • cGMP is metabolized to physiologically inactive 5'-GMP by the action of cGMP phosphodiesterase (abbreviated as cGMPoPDE hereafter).
  • the inhibition of the action of cGMP-PDE is considered to be useful for the prevention and/or treatment of diseases induced by enhancement of the metabolism of cGMP, such as hypertension, heart failure, myocardial infarction, angina, atherosclerosis, cardiac edema, renal insufficiency, nephrotic edema, hepatic edema, asthma, bronchitis, dementia, immunodeficiency, pulmonary hypertension.
  • diseases induced by enhancement of the metabolism of cGMP such as hypertension, heart failure, myocardial infarction, angina, atherosclerosis, cardiac edema, renal insufficiency, nephrotic edema, hepatic edema, asthma, bronchitis, dementia, immunodeficiency, pulmonary hypertension.
  • TXA 2 thromboxane A2
  • TXA 2 thromboxane A2
  • TXA 2 is biosynthesized from arachidonic acid released from cell membrane via prostaglandin G 2 and prostaglandin H 2 , and rapidly metabolized to inactive thromboxane B 2 .
  • TXA 2 is known to induce platelet aggregation and to contract smooth muscle, particularly blood vessel muscle and bronchial muscle.
  • TXA 2 synthetase was isolated and purified from microsome in platelets.
  • TXA 2 synthetase decreases the biosynthesis of TXA 2 , and is useful for the prevention and/or treatment of inflammation, hypertension, thrombosis, arteriosclerosis, cerebral apoplexy, asthma, myocardial infarction, cardiostenosis, cerebral infarction, etc.
  • quinazoline derivatives having inhibitory activity on cGMP-PDE have been laid open (see WO 93/07124).
  • the quinazoline derivatives of the following formula is disclosed. ##STR5## wherein ring A e is, for example, benzene, cyclohexane; ring B e is, for example, pyrimidine;
  • R 1e , R 2e , R 3e and R 4e are each, for example, hydrogen, halogen, lower alkyl optionally substituted by halogen, lower alkoxy, hydroxyalkyl, nitro, cyano, acylamino, optionally protected COOH, S(O)n e --R 7e (n e is 0,1,2, R 7e is lower alkyl), NR 45e R 46e (R 45e and R 46e are each, for example, hydrogen, lower alkyl);.
  • R 5e is, for example, optionally substituted heteroaryl (for example, pyridinyl, imidazolidinyl, qunazolidinyl);
  • R 6e is, for example, ##STR6##
  • R 17e is, for example, hydrogen, lower alkyl, alkoxyalkyl, hydroxyalkyl
  • Y e is, for example, (CH 2 )q e (q e is 0 to 8); R 18e is, for example, hydrogen, hydroxy, optionally substituted heteroaryl, optionally substituted cycloalkyl), ##STR7##
  • R 19e is, for example, hydrogen, lower alkyl
  • R 20e , R 21 e and R 22e are each, for example, hydrogen, halogen, nitro, low alkyl, alkoxy
  • r e is 0 to 8
  • TXA 2 synthetase inhibitors have been known, for example, ##STR8##
  • the present invention relates to:
  • Y is single bond or C1-6 alkylene
  • R 0 is R 0A or ROB
  • R 0A is --CyA--(R 2 )l
  • R OB is hydrogen or C1-4 alkyl; p is 0-2;
  • R 2 is R 2A or R 2B ;
  • R 2A is (1)--NRGAR 7A , in which R 6A and R 7A independently are hydrogen or C1-4 alkyl (with the proviso that R 6A and R 7A are not hydrogen at same time), (2) -SO2NRGR 7 , in which R 6 and R 7 independently are hydrogen or C1-4 alkyl, (3) trifluoromethyl or (4) trifluoromethoxy;
  • R 2B is (1) hydrogen, (2) C1-4 alkyl, (3) C1-4 alkoxy, (4)--COOR 5 , in which R 5 is hydrogen or C1-4 alkyl, (5) halogen, (6) nitro or (7) --NRGBR 7B , in which R 6B and R 7B are hydrogen;
  • Z is Z A or Z B ;
  • Z A is methylene, ethylene (CH 2 CH 2 ), vinylene (CH ⁇ CH) or ethynylene (C.tbd.C);
  • Z B is single bond
  • R3 is hydrogen, C1-4 alkyl, C1-4 alkoxy, halogen or trifluoromethyl
  • R 4 is R 4A or R 4B ;
  • R 4A is (1) --NHSO 2 R 11 , in which R 11 is C1-4 alkyl, (2) SO 2 NR 9 R 10 , in which R 9 is hydrogen, C1-4 alkyl or phenyl(C1-4 alkyl) and R 10 is hydrogen or C1-4 alkyl, (3) --OCOR 11 , in which R 11 is as hereinbefore defined, (4) hydroxy, (5) --SO 2 N ⁇ CHNR 12 R 13 in which R 12 is hydrogen or C1-4 alkyl and R 13 is C1-4 alkyl, (6) --CONR 4 R 15 in which R 14 is hydrogen or C1-4 alkyl and R 15 is C1-4 alkyl or phenyl(C1-4 alkyl), (7) ethynyl, (8) tri(C1-4 alkyl)silylethynyl or (9) acetyl;
  • R 4B is (1) hydrogen, (2) C1-4 alkyl, (3) C1-4 alkoxy, (4)-COOR 8 , in which R8 is hydrogen or C1-4 alkyl, (5) --NR 9 R 10 , in which R 9 and R 10 are as hereinbefore defined, (6) --NHCOR 11 , in which R 11 is as hereinbefore defined, (7) halogen, (8) trifluoromethyl, (9) nitro, (10) cyano, (11) C1-4 alkylthio, (12) C1-4 alkylsulfinyl, (13) C1-4 alkylsulfonyl, (14) hydroxymethyl, and l, m and n independently are 1 or 2; with the proviso that
  • a CyB ring should not bond to Z through a nitrogen atom in the CyB ring when Z is vinylene or ethynylene, that
  • CyB ring should not be pyridine or thiophene when CyA is a ring of CyA--(7), that
  • Y is not a single bond, when A is (ii) --O--RO or --S(O)p-R 0 and that
  • A should not be --CyA--(R 2 B)l and --OR 0B , when Z is Z B and R 4 is R 4 B; or pharmaceutically acceptable acid addition salts thereof, pharmaceutically acceptable salts thereof, or hydrates thereof,
  • This present invention can be classified in three groups of the formula indicated as follows;
  • Z A in the formula [I-(A)] dose not represent a single bond (that is, CyB is bonded to the quinazoline skeleton through a carbon chain.), but in the formula (E), R 5e (heteroaryl) is directly bonded to the skeleton ring B e ,
  • R 4A in the formula [I-(B)] represents definite groups, i.e., sulfonylamino, aminosulfonyl, acyloxy, hydroxy, --SO 2 N ⁇ CHNR 12 R 13 , aminocarbonyl, ethynyl, tri(C1-4alkyl)silylethynyl, acetyl group, but R 1e to R 4e in the formula (E) do not represent them at all,
  • a C in the formula [I-(C)] represents oxygen-containing group (i.e., 0--CyA-(R 2 )l), but R 6e in the formula (E) dose not represent the group of O-cyclic ring, and
  • a C in the formula [I-(C)] represents sulfur-containing group (i.e., S(O)p--R 0 ), but R 6e in the formula (E) does not represent such a group.
  • the compounds of the present invention are quite novel. Furthermore, the fact that compounds of the present invention have inhibitory activity on cGMP-PDE or additionally TXA 2 synthetase, is not suggested from pharmaceutical use disclosed in any related arts mentioned above. Accordingly, the compounds of the present invention are useful for the prevention and/or treatment of diseases induced by only enhancement of the metabolism of cGMP, or the increase of TXA 2 , or induced by both factors.
  • the C1-4 alkyl group represented by R 0 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 and R 15 mean methyl, ethyl, propyl, butyl and the isomers thereof.
  • the C1-4 alkoxy group represented by R 2 , R 3 and R 4 mean methoxy, ethoxy, propoxy, butoxy and isomers thereof.
  • the halogen atom represented by R 2 , R 3 and R 4 mean fluorine, chlorine, bromine and iodine.
  • the C1-6 alkylene group represented by Y means methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene and isomers thereof.
  • examples of 3-7 membered, saturated or unsaturated, monocyclic carbocyclic ring represented by CyA--(1), are cyclobutadiene, cyclopentadiene, benzene, cycloheptatriene ring, and partially or fully saturated rings thereof, for example, cyclobutane, cyclopentane, cyclohexane, cycloheptane ring, and cyclopropane ring.
  • Examples of 7-membered, unsaturated or partially saturated, monocyclic hetero ring containing as hetero atoms, one nitrogen atom, one nitrogen and one oxygen atoms, two nitrogen and one oxygen atoms, or one nitrogen and two oxygen atoms, represented by CyA--(2), are azepine, oxazepine, and partially saturated rings thereof.
  • 6-membered, unsaturated or partially saturated, monocyclic hetero ring containing as hetero atoms, one nitrogen and one oxygen atoms, two nitrogen and one oxygen atoms, or one nitrogen and two oxygen atoms, represented by CyA--(3), are oxazine, oxadiazine, and partially saturated rings thereof.
  • 6-membered, unsaturated or partially saturated, monocyclic hetero ring containing as hetero atoms, one nitrogen atom, represented by CyA--(4) and CyB-(3), are pyridine, dihydropyridine, and tetrahydropyridine.
  • Examples of 4- or 5-membered, unsaturated or partially saturated, monocyclic hetero ring containing as hetero atoms, one nitrogen atom, one nitrogen and one oxygen atoms, two nitrogen and one oxygen atoms, or one nitrogen and two oxygen atoms, represented by CyA--(5), are pyrrole, azetine, oxazole, isoxazole, furazan, and partially saturated rings thereof.
  • Examples of 4-7 membered, unsaturated or partially saturated, monocyclic hetero ring containing as hetero atoms, one or two sulfur atoms, represented by CyA--(6), are thiophene, thiain, dithiain, and partially saturated rings thereof.
  • Examples of 4-7 membered, unsaturated or partially or fully saturated, monocyclic hetero ring containing as hetero atom one oxygen atom represented by CyA--(7), are furan, pyran, dioxin and partially or fully saturated rings thereof.
  • examples of 7-membered, unsaturated or partially saturated, monocyclic hetero ring containing as hetero atoms, one, two or three nitrogen atoms, represented by CyB-(1 ), are azepine, diazepine, triazepine, and partially saturated rings thereof.
  • Examples of 6-membered, unsaturated or partially saturated, monocyclic hetero ring containing as hetero atoms, two or three nitrogen atoms, represented by CyB-(2) are pyridazine, pyrimidine, pyrazine, triazine, and partially saturated rings thereof.
  • Examples of 4- or 5-membered, unsaturated or partially saturated, monocyclic hetero ring containing as hetero atoms, one, two or three nitrogen atoms, represented by CyB-(4), are pyrrole, imidazole, pyrazole, triazole, azetine, and partially saturated rings thereof,
  • Examples of 4-7 membered, unsaturated or partially saturated, monocyclic hetero ring containing as hetero atoms, one or two oxygen atoms, or one or two sulfur atoms represented by CyB-(5), are thiophene, furan, thiain, pyran, dithiain, dioxin, dioxole, and partially saturated rings thereof.
  • the compounds of the formula (I), if desired, may be converted into acid addition salts by known methods.
  • acid addition salts are non-toxic and water-soluble.
  • the suitable acid addition salts are, for example, salts of an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, nitric acid, or an organic acid such as acetic acid, lactic acid, tartaric acid, benzoic acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, isethionic acid, glucuronic acid and gluconic acid.
  • an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, nitric acid
  • an organic acid such as acetic acid, lactic acid, tartaric acid, benzoic acid, citric acid, methane
  • salts are non-toxic salts and water-soluble.
  • the suitable salts are salts of alkaline metal (sodium, potassium etc.), salts of alkaline earth metal (calcium, magnesium etc.), ammonium salts, salts of pharmaceutically acceptable organic amine (tetramethylammonium, triethylamine, methylamine, dimethylamine, cyclopentylamine, phenylmethylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)methylamine, lysine, arginine, N-methyl-D-glucamine etc.).
  • alkyl, alkoxy, groups include straight-chained and also branched-chained ones. Accordingly, all isomers produced by the difference in stereo configuration, such as asymmetric carbons are included in the present invention.
  • R 41 is (1) hydrogen, (2) C1-4 alkyl, (3) C1-4 alkoxy, (4) --COOR 8 , (5) --NR 91 R 101 , in which R 91 is hydrogen, C1-4 alkyl or phenyl(C1-4 alkyl) and R 101 is hydrogen or C1-4 alkyl, provided that both R 91 and R 101 are not hydrogen, (6) SO 2 NR 9 R 10 , in which R 9 and R 10 are as hereinbefore defined, (7) halogen, (8)trifluoromethyl, (9) nitro, (10)cyano, (11)C1-4 alkylthio, (12) tri(C1-4 alkyl)silylethynyl, (13) --SO 2 N ⁇ CHNR 12 R 13 , in which R 12 and R 13 are the same meaning as hereinbefore defined, or (14) --CONR 14 R 15 , in which R 14 and R 15 are the same meaning as hereinbefore defined, CyB 1
  • the compounds of the formula (IA) may be prepared from those of the formula (V) by the reaction with an amine of the formula (IX) in a proper organic solvent such as a lower alkanol (e.g. ethanol) or tetrahydrofuran, or a mixture thereof, at a temperature from ambient to reflux, for several hours to several days, if necessary in the presence of a base such as triethylamine.
  • a proper organic solvent such as a lower alkanol (e.g. ethanol) or tetrahydrofuran, or a mixture thereof, at a temperature from ambient to reflux, for several hours to several days, if necessary in the presence of a base such as triethylamine.
  • the compounds of the formula (IB) may be prepared from those of the formula (XII) by the reaction with a cyclic amine of the formula (XVI) in phenol at a reflux temperature for several hours.
  • the compounds of the present invention may be prepared from those of the formula: ##STR17## wherein the various symbols are as hereinbefore defined; by the methods described hereinbefore for the conversion of the compounds of the formula (V) into those of the formula (IA).
  • the compounds of the formula (XVII) may be prepared by the methods similar to those described hereinbefore in Scheme A.
  • the compounds of the formula (I) other than those of the formulae (IA), (lB) and (IC) may be prepared by the methods known per se described below.
  • the compounds of the formula (I) wherein R 4 is amino may be prepared from those wherein R 4 is nitro, by the reduction with zinc etc. in a proper organic solvent.
  • R 4 is hydroxy
  • R 4 is alkoxy such as methoxy
  • R 4 is--NHCOR 11 , wherein R 11 is as hereinbefore defined, may be prepared from those wherein R 4 is nitro, by the reaction with the corresponding organic acid such as acetic acid in the presence of zinc dust.
  • R 4 is NHSO 2 R 11 , wherein R 11 is as hereinbefore defined
  • R 4 is amino by the reaction with the corresponding alkylsulfonyl chloride such as methanesulfonyl chloride.
  • R 4 is --OCOR 11 , wherein R 11 is as hereinbefore defined, may be prepared from those wherein R 4 is hydroxy by the esterification with the corresponding organic acid such as acetic acid.
  • R 4 is C1-4 alkylsulfinyl or C1-4 alkylsulfonyl
  • R 4 is C1-4 alkylthio by the oxidation by oxidating agent such as hydrogen peroxide.
  • the compounds of the formula (I) wherein R 4 is hydroxymethyl may be prepared from those wherein R 4 is alkyoxycarbonyl, by the reduction with reducing agent such as lithium borohydride, lithium aluminum hydride etc.
  • the compounds of the formula (I) wherein R 4 is ethynyl may be prepared from those wherein R 4 is tri(C1-4 alkyl)silylethynyl, by the removal reaction of silyl group with tetrabutylammonium halide.
  • the compounds of the formula (I) wherein R 4 is acetyl may be prepared from those wherein R 4 is ethynyl, by the reaction with mercury sulfate and acetic acid in an acidic condition.
  • products may be purified by conventional manner. For example, it may be carried out by distillation at atmospheric or reduced pressure, high performance liquid chromatography, thin layer chromatography or column chromatography using silica gel or magnesium silicate, washing or recrystallization. Purification may be carried out after each reaction, or after a series of reactions.
  • the starting materials of the formulae (II), (VI) and (XIII), and each reagents of the formulae (VII), (VIII), (IX), (XV), (XVI), (XVII) and (XVIII) used in the process for the preparation of the present invention are known per se or may be easily prepared by known methods.
  • the compounds of the formula (I), pharmaceutically acceptable acid addition salts thereof, pharmaceutically acceptable salts thereof, or hydrates thereof, of the present invention have an inhibitory effect on cGMPPDE, or additionally on TXA 2 synthetase, and are, therefore, useful for the prevention and/or treatment of not only diseases induced by enhancement of the metabolism of cGMP, such as hypertension, heart failure, myocardial infarction, angina, atherosclerosis, cardiac edema, renal insufficiency, nephrotic edema, hepatic edema, asthma, bronchitis, dementia, immunodeficiency, pulmonary hypertension, but also diseases induced by enhancement of the synthesis of TXA 2 such as inflammation, thrombosis, cerebral apoplexy, asthma, cardiostenosis, cerebral infarction etc, in mammals, especially in humans.
  • diseases induced by enhancement of the synthesis of TXA 2 such as inflammation, thrombosis, cerebral apoplexy, asthma,
  • PDE IC was isolated from human platelets according to standard methods previously described in Lugnier, C. et al., Biochem. Pharmacol. 35: 1743, 1986 (incorporated in its entirety by reference). Typically, connective tissue and adventitia were removed and 1-2 units of platelets were suspended in 10 volumes of buffer A (20 mM Tris-HCl, pH 7.5, containing 2 mM magnesium acetate, 1 mM dithiothreitol, and 5 mM Na2EDTA) using a Brinkman polytron. The proteinase inhibitors leupeptin, pepstatin A, and phenylmethyl-sulfonyl fluoride (PMSF) were also included in this buffer (final concentration of 100 nM each).
  • buffer A (20 mM Tris-HCl, pH 7.5, containing 2 mM magnesium acetate, 1 mM dithiothreitol, and 5 mM Na2EDTA
  • PMSF phenylmethyl-sulfony
  • the homogenate was centrifuged at 100,000g for 60 minutes. The supernatant was then removed and filtered through four layers of cheesecloth. The supernatant was applied to a DWAE-Trisacryl M column. The column was washed with several bed volumes of buffer B (20 mM Tris-HCl, pH 7.5, containing 2 mM magnesium acetate, 1 mM dithiothreitol, and proteinase inhibitors) and eluted by two successive linear NaCl gradients (0.05-0.15M, 300 ml total; 0.15-0.40M, 200 ml total). Five milliliter fractions were collected and assayed for cyclic GMP PDE activity.
  • buffer B 20 mM Tris-HCl, pH 7.5, containing 2 mM magnesium acetate, 1 mM dithiothreitol, and proteinase inhibitors
  • Phosphodiesterase activity was measured, as described by Thompson, et al., Adv. Cyclic Nucleotide Res. 10: 69, 1979 (incorporated in its entirety by reference), in a reaction medium containing 40 mM Tris-HCl (pH 8.0), 5 mM MgCl2, and 1 mM dithiothreitol.
  • the concentration of substrate ( 3 H-cGMP) was 0.2 mM.
  • Compounds of the present invention were dissolved in dimethyl sulfoxide (DMSO) at a final concentration of 2.5%. This concentration of DMSO inhibited enzyme activity by approximately 10%.
  • DMSO dimethyl sulfoxide
  • the IC 50 values concentration that produced 50% inhibition of substrate hydrolysis
  • the compounds of the present invention may be considered to be sufficiently safe and suitable for pharmaceutical use.
  • the compounds, of the formula (I), of the present invention, pharmaceutically acceptable acid addition salts thereof and hydrates thereof may be normally administered systemically or partially, usually by oral or parenteral administration.
  • the doses to be administered are determined depending upon age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment etc.
  • the doses per person are generally between 1 mg and 1000 mg, by oral administration, up to several times per day, and between 1 mg and 100 mg, by parenteral administration up to several times per day, or continuous administration between 1 and 24 hrs. per day intravenously.
  • the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.
  • Administration of the compounds of the present invention may be as solid compositions, liquid compositions or other compositions for oral administration, as injections, liniments or suppositories etc. for parenteral administration.
  • Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules.
  • Capsules include hard capsules and soft capsules.
  • one or more of the active compound(s) is or are, admixed with at least one inert diluent (such as lactose, mannitol, glucose, hydroxypropyl cellulose, micro crystalline cellulose, starch, polyvinylpyrrolidone, magnesium metasilicate aluminate etc.)
  • the compositions may also comprise, as is normal practice, additional substances other than inert diluents: e.g. lubricating agents (such as magnesium stearate etc.), disintegrating agents (such as cellulose calcium glycolate etc.), stabilizing agents (such as lactose etc.), and assisting agents for dissolving (such as glutamic acid, aspartic acid etc.).
  • the tablets or pills may, if desired, be coated with film of gastric or enteric material (such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropylmethyl cellulose phthalate etc.), or be coated with more than two films. And further, coating may include containment within capsules of absorbable materials such as gelatin.
  • gastric or enteric material such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropylmethyl cellulose phthalate etc.
  • Liquid compositions for oral administration include pharmaceutically-acceptable solutions, emulsions, suspensions, syrups and elixirs.
  • one or more of the active compound(s) is or are comprise in inert diluent(s) commonly used in the art (purified water, ethanol etc.).
  • compositions may also comprise adjuvants (such as wetting agents, suspending agents etc.), sweetening agents, flavouring agents, perfuming agents and preserving agents.
  • adjuvants such as wetting agents, suspending agents etc.
  • compositions for oral administration include spray compositions which may be prepared by known methods and which comprise one or more of the active compound(s).
  • Spray compositions may comprise additional substances other than inert diluents: e.g. stabilizing agents (sodium sulfite etc.), isotonic buffer (sodium chloride, sodium citrate, citric acid etc.)
  • stabilizing agents sodium sulfite etc.
  • isotonic buffer sodium chloride, sodium citrate, citric acid etc.
  • Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions.
  • one more of active compound(s) is or are admixed with at least one of inert aqueous diluent(s) (distilled water for injection, physiological salt solution etc.) or inert non-aqueous diluent(s) (propylene glycol, polyethylene glycol, olive oil, ethanol, POLYSOLBATE80 (registered trade mark) etc.).
  • inert aqueous diluent(s) distilled water for injection, physiological salt solution etc.
  • inert non-aqueous diluent(s) propylene glycol, polyethylene glycol, olive oil, ethanol, POLYSOLBATE80 (registered trade mark) etc.
  • Injections may comprise additional other than inert diluents: e.g. preserving agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agent (lactose etc.), assisting agents such as assisting agents for dissolving (glutamic acid, aspartic acid etc.).
  • inert diluents e.g. preserving agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agent (lactose etc.), assisting agents such as assisting agents for dissolving (glutamic acid, aspartic acid etc.).
  • They may be sterilized for example, by filtration through a bacteria-retaining filter, by incorporation of sterilizing agents in the compositions or by irradiation. They also be manufactured in the form of sterile solid compositions, for example, by freeze- drying, and which can be dissolved in sterile water or some other sterile diluents for injection immediately before used.
  • compositions for parenteral administration include liquids for external use, and endermic liniments (ointment etc.), suppositories and pessaries which comprise one or more of the active compound(s) and may be prepared by known methods.
  • the product was collected by filtration as a pale solid.
  • the product was collected by filtration as a pale solid.
  • the product was collected by filtration as a pale brown.
  • the product was collected by filtration as a solid.
  • the product was collected by filtration as a white solid.
  • the product was collected by filtration as a white solid.
  • the product was collected by filtration as a white solid.
  • the product was collected by filtration as a brown solid.
  • the product was collected by filtration as a tan powder.
  • the product was collected by the filtration as a tan powder.
  • the product was collected by filtration as a white solid.
  • Example 1 The following compounds were obtained by the same procedure as Example 1, or Example 1 and Example 2, by using the corresponding 4-chloroquinazoline compound prepared by Reference example 5, 5(a) to 5(e) or Reference example 8, 8(a) to 8(d) and the proper amine.
  • the product was collected by filtration as a white solid.
  • the product was collected by filtration as a white powder.
  • the product was purified by column chromatography.
  • the product was collected by filtration as a white powder.
  • the product was collected by filtration as a white solid.
  • the product was collected by filtration as a white solid.
  • the product was collected by filtration as a tan solid.
  • the product was collected by filtration as a yellow powder.
  • the product was collected by filtration as a yellow powder.
  • the product was collected by filtration as a white solid.
  • the product was collected by filtration as a white powder.
  • the product was collected by filtration as a solid.
  • the product was collected by filtration as a solid.
  • Example 2 The title compound having the following physical data, was obtained by the same procedure as Example 2, by using the free base prepared in Example 5 and HCl/methanol solution.
  • the title compound having the following physical data was obtained by the same procedure as Example 1, by using the 4-chloro compound prepared in Reference example 16 and phenylmethylamine.
  • the product was purified by column chromatography.
  • the following components were admixed in conventional method and punched out to obtain 100 tablets each containing 50 mg of active ingredient.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
US08/154,518 1992-07-15 1993-11-19 4-aminoquinazoline derivatives Expired - Fee Related US5436233A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/154,518 US5436233A (en) 1992-07-15 1993-11-19 4-aminoquinazoline derivatives

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91347392A 1992-07-15 1992-07-15
US7643193A 1993-06-14 1993-06-14
US08/154,518 US5436233A (en) 1992-07-15 1993-11-19 4-aminoquinazoline derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US7643193A Continuation-In-Part 1992-07-15 1993-06-14

Publications (1)

Publication Number Publication Date
US5436233A true US5436233A (en) 1995-07-25

Family

ID=26758098

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/154,518 Expired - Fee Related US5436233A (en) 1992-07-15 1993-11-19 4-aminoquinazoline derivatives
US08/154,691 Expired - Fee Related US5439895A (en) 1992-07-15 1993-11-19 4-aminoquinazoline derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
US08/154,691 Expired - Fee Related US5439895A (en) 1992-07-15 1993-11-19 4-aminoquinazoline derivatives

Country Status (11)

Country Link
US (2) US5436233A (de)
EP (1) EP0579496B1 (de)
JP (2) JP2657760B2 (de)
KR (1) KR100191416B1 (de)
AT (1) ATE208771T1 (de)
CA (1) CA2100626A1 (de)
DE (1) DE69331122T2 (de)
DK (1) DK0579496T3 (de)
ES (1) ES2167325T3 (de)
PT (1) PT579496E (de)
TW (1) TW341566B (de)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707998A (en) * 1993-03-31 1998-01-13 Eisai Co., Ltd. Nitrogen-containing fused-heterocycle compounds
WO1999032460A1 (de) * 1997-12-18 1999-07-01 Aventis Pharma Deutschland Gmbh Substituierte 2-aryl-4-amino-chinazoline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2000037061A2 (en) * 1998-12-22 2000-06-29 Novartis Ag cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION
US6130223A (en) * 1996-10-24 2000-10-10 Merck Patent Gesellschaft Mit Beschrankter Haftung Thienopyrimidine with phosphodiesterase V inhibiting effect
WO2001045641A2 (en) * 1999-11-30 2001-06-28 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
WO2001068615A1 (en) * 2000-03-13 2001-09-20 Chemrx Advanced Technologies, Inc. Quinazoline synthesis
US6300335B1 (en) * 1994-11-26 2001-10-09 Pfizer Inc. 4-aminoquinazoline derivative cGMP-PDE inhibitors for the treatment of erectile dysfunction
WO2002011707A2 (en) * 2000-08-08 2002-02-14 Nicox S.A. Drugs for incontinence
WO2002043735A1 (en) * 2000-11-29 2002-06-06 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
US20030105114A1 (en) * 2001-09-28 2003-06-05 Carpino Philip A. Methods of treatment and kits comprising a growth hormone secretagogue
US20030214965A1 (en) * 2002-03-13 2003-11-20 Liping Chen Method and apparatus for one directional communications in bidirectional communications channel
US20040023990A1 (en) * 2000-11-25 2004-02-05 Hans-Michael Eggenweiler Use of pyrazolo[4,3-d]pyrimidines
US20040029900A1 (en) * 2000-06-29 2004-02-12 Rochus Jonas 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect
US20040063690A1 (en) * 1999-02-05 2004-04-01 Aventis Pharma Deutschland Gmbh Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them
US20050004110A1 (en) * 2000-09-15 2005-01-06 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
WO2004092196A3 (en) * 2003-04-09 2005-03-17 Exelixis Inc Tie-2 modulators and methods of use
US20050119273A1 (en) * 2003-06-20 2005-06-02 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (TLR) antagonists
WO2005087227A1 (en) * 2004-03-04 2005-09-22 Neurogen Corporation Arylalkylamino-substituted quinazoline analogues
SG121687A1 (en) * 1999-03-31 2006-05-26 Pfizer Prod Inc Processes and intermediates for preparing anti-cancer compounds
US20060258693A1 (en) * 2003-08-08 2006-11-16 Suzanne Chamberland Halogenated quinazolinyl nitrofurans as antibacterial agents
US20070208044A1 (en) * 2003-07-03 2007-09-06 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
US20070293667A1 (en) * 2001-09-17 2007-12-20 Werner Mederski 4-Amino-quinazolines
US20080051398A1 (en) * 2005-01-03 2008-02-28 Myriad Genetics, Inc. Method of treating brain cancer
US20080146562A1 (en) * 2003-08-08 2008-06-19 Ulysses Pharmaceutical Products Inc., Halogenated quinazolinyl nitrofurans as antibacterial agents
USRE41065E1 (en) 1995-06-06 2009-12-29 Pfizer, Inc. Alkynl and azido-substituted 4-anilinoquinazolines
US20100069383A1 (en) * 2003-07-03 2010-03-18 Myriad Pharmaceuticals, Incorporated Compounds and therapeutical use thereof
US20100317659A1 (en) * 2009-02-27 2010-12-16 Sunny Abraham Jak kinase modulating compounds and methods of use thereof
EP2286813A2 (de) 2006-01-31 2011-02-23 Novartis AG Verwendung von Naphthyridin-Derivaten als Heilmittel
US7989462B2 (en) 2003-07-03 2011-08-02 Myrexis, Inc. 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20110190192A1 (en) * 2009-12-15 2011-08-04 Cebix Inc. Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
US20130245052A1 (en) * 2010-11-26 2013-09-19 Hetero Research Foundation Novel polymorph of nilotinib hydrochloride
US8633207B2 (en) 2010-09-01 2014-01-21 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
CN110291073A (zh) * 2016-12-13 2019-09-27 贝塔医疗私人有限公司 乙酰肝素酶抑制剂及其用途
CN113195470A (zh) * 2018-09-13 2021-07-30 南加州大学 作为治疗剂的新型单磷酸鸟苷合成酶抑制剂

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
AU2096895A (en) * 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
HU219864B (hu) 1994-08-09 2001-08-28 Eisai Co., Ltd. cGMP-PDE inhibitor kondenzált piridazinszármazékok és alkalmazásuk
US5486519A (en) * 1994-08-22 1996-01-23 Greenwald; James E. Method for treatment of acute renal failure
EP0794178A4 (de) * 1994-11-25 1998-02-25 Nippon Chemiphar Co Chinazolin-derivate
US5658902A (en) * 1994-12-22 1997-08-19 Warner-Lambert Company Quinazolines as inhibitors of endothelin converting enzyme
US5869486A (en) * 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
EP0757984B1 (de) * 1995-08-08 2002-10-30 Ono Pharmaceutical Co., Ltd. Hydroxamsäurederivate verwendbar zur Hemmung von Gelatinase
DE69614986T2 (de) * 1995-12-26 2002-04-25 Sumitomo Chemical Co., Ltd. Verfahren zur Herstellung von Isatosäureanhydriden
FR2750862B1 (fr) * 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
DE19632423A1 (de) * 1996-08-12 1998-02-19 Merck Patent Gmbh Thienopyrimidine
EP0977756A1 (de) 1997-04-25 2000-02-09 Pfizer Limited Pyrazolopyrimidinone, die den typ 5 der cyclischen guanosin 3',5'-monophosphat phospodiesterase (cgmp pde5) hemmen, zur behandlung von sexuellen funktionsstörungen
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5939421A (en) * 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
DE19819023A1 (de) * 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
CA2403605A1 (en) 2000-03-31 2002-09-18 Kazuya Mori Heterocycle derivatives and drugs
US6828473B2 (en) 2000-11-01 2004-12-07 Pfizer Inc. Modulation of PDE11A activity
EP1211313A3 (de) * 2000-11-01 2003-04-23 Pfizer Limited Modulation der PDE11A-AKtivität
EP1340748B1 (de) * 2000-11-02 2008-01-16 Nippon Shinyaku Co., Ltd. Chinazolinderivate und -arzneimittel
WO2002062767A1 (fr) * 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Nouveaux derives de quinazoline
RU2003130752A (ru) * 2001-03-19 2005-03-10 Ниппон Синяку Ко., Лтд. (Jp) Противозудные средства
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
US7176314B2 (en) 2001-12-05 2007-02-13 Amgen, Inc. Inflammation modulators
AU2002361846A1 (en) * 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
WO2003086373A1 (en) * 2002-04-12 2003-10-23 Celgene Corporation Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
WO2003087333A2 (en) * 2002-04-12 2003-10-23 Celgene Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CA2494367A1 (en) * 2002-07-25 2004-02-05 Scios Inc. Methods for improvement of lung function using tgf-.beta. inhibitors
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
ATE417849T1 (de) 2004-04-07 2009-01-15 Pfizer Pyrazoloä4,3-düpyrimidine
KR20060079121A (ko) * 2004-12-31 2006-07-05 에스케이케미칼주식회사 당뇨 및 비만 치료예방에 유효한 퀴나졸린 유도체
US8252806B2 (en) 2005-03-14 2012-08-28 Neurosearch A/S Potassium channel modulating agents and their medical use
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP2009519995A (ja) * 2005-12-20 2009-05-21 ノイロサーチ アクティーゼルスカブ 呼吸器疾患の治療のためのカリウムチャンネル調節剤としての２−ピリジン−２−イル−キナゾリン誘導体
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
KR101040994B1 (ko) * 2006-04-13 2011-06-16 코오롱인더스트리 주식회사 포지티브형 포토레지스트 필름
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008092942A2 (en) * 2007-02-02 2008-08-07 Neurosearch A/S Pyridinyl-pyrazole derivatives and their use as potassium channel modulators
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2077263A1 (de) * 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Chinazoline und verwandte heterocyclische Verbindungen und ihre therapeutische Verwendung
CA2718412A1 (en) * 2008-03-24 2009-10-01 Celgene Corporation Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
EP2321341B1 (de) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
EP2241565A1 (de) 2009-01-15 2010-10-20 Universität Leipzig Aurora-Kinase-Inhibitor-Verbindungen
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MY160243A (en) 2009-09-03 2017-02-28 Bristol Myers Squibb Co Quinazolines as potassium ion channel inhibitors
AR079814A1 (es) * 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN108676076A (zh) 2011-03-01 2018-10-19 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
AR086798A1 (es) * 2011-06-29 2014-01-22 Otsuka Pharma Co Ltd Derivados quinazolinicos utiles para tratar trastornos del sistema nervioso central y composiciones farmaceuticas que los contienen
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
AU2013370417A1 (en) 2012-12-28 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof
EP2769723A1 (de) * 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Verbindungen zur Verwendung bei der Hemmung einer HIV-Kapsid-Anordnung
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
EP2970384A1 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonisten der guanylatcyclase und deren verwendungen
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
WO2015112739A1 (en) * 2014-01-22 2015-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for treating parp1-deficient cancers
ES2749433T3 (es) 2014-06-23 2020-03-20 Celgene Corp Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
US10087148B2 (en) 2014-12-05 2018-10-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institute Of Health Quinazolines as biogenic amine transport modulators
EP3226867A4 (de) * 2014-12-05 2018-05-09 Subramaniam Ananthan Heterocyclische verbindungen als biogene amintransportmodulatoren
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3324122A (en) * 1964-12-14 1967-06-06 Norwich Pharma Co Series of 4-substituted-2-(5-nitro-2-furyl) quinazolines
GB1199768A (en) * 1966-10-31 1970-07-22 Pfizer & Co C Nitrogen Heterocycles and process for their preparation
FR2081456A1 (de) * 1970-01-26 1971-12-03 Norwich Pharma Co
FR2102221A1 (en) * 1970-08-12 1972-04-07 Squibb & Sons Inc 4-amino-(2-(5-nitro-2-furyl) vinyl)-quinazolines - antimicrobial gastrointestinal sterilisation agents
US3753981A (en) * 1970-07-15 1973-08-21 Squibb & Sons Inc 4-amino-2-styrylquinazoline compounds
US3772295A (en) * 1970-02-16 1973-11-13 Innothera Lab Sa Quinazoline derivatives
US3819628A (en) * 1972-07-31 1974-06-25 Sandoz Ag 2-phenyl-4-substituted amino-quinazolines and nitrates thereof
SU461621A1 (ru) * 1971-12-21 1975-11-25 Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе Способ получени замещенных 4-амино-2стирилхиназолинов
US3971783A (en) * 1973-03-07 1976-07-27 Pfizer Inc. 4-Aminoquinazoline derivatives as cardiac stimulants
CH578556A5 (en) * 1973-02-20 1976-08-13 Sandoz Ag 2-(5-Nitro-heterocyclyl)-substd 4-amino-quinazolines - with bactericidal, trichomonacidal and amoebicidal activity
FR2310756A1 (fr) * 1975-05-12 1976-12-10 Sandoz Sa Nouveaux derives de la quinazoline, leur preparation et leur application comme medicaments
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB2002746A (en) * 1977-06-17 1979-02-28 Gist Brocades Nv Copper complexes
US4306065A (en) * 1979-12-19 1981-12-15 A. H. Robins Company, Incorporated 2-Aryl-4-substituted quinazolines
JPS58172379A (ja) * 1982-04-02 1983-10-11 Showa Denko Kk 新規なキナゾリン誘導体
EP0135975A2 (de) * 1983-09-29 1985-04-03 Akzo N.V. Chinazolin- und Isochinolin-Derivate
WO1989005297A1 (en) * 1987-12-03 1989-06-15 Smithkline Beckman Intercredit B.V. Compounds
EP0371731A2 (de) * 1988-11-30 1990-06-06 Smith Kline & French Laboratories Limited Chinazolinon-Derivate
EP0395328A2 (de) * 1989-04-26 1990-10-31 Smith Kline & French Laboratories Limited Phenylpyrimidone Derivaten und ihre Anwendung als therapeutisches Mittel
US5047404A (en) * 1988-06-16 1991-09-10 Smith Kline & French Laboratories, Ltd. Chemical compounds
WO1993007124A1 (en) * 1991-09-30 1993-04-15 Eisai Co., Ltd. Nitrogenous heterocyclic compound

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922735A1 (de) * 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3324122A (en) * 1964-12-14 1967-06-06 Norwich Pharma Co Series of 4-substituted-2-(5-nitro-2-furyl) quinazolines
GB1199768A (en) * 1966-10-31 1970-07-22 Pfizer & Co C Nitrogen Heterocycles and process for their preparation
FR2081456A1 (de) * 1970-01-26 1971-12-03 Norwich Pharma Co
US3705898A (en) * 1970-01-26 1972-12-12 Morton Norwich Products Inc Certain 4 - amino - 2-(5-nitro-2-thienyl) quinazolines and the intermediate 4 - chloro-(5 - nitro-2-thienyl)quinazolines therefor
US3772295A (en) * 1970-02-16 1973-11-13 Innothera Lab Sa Quinazoline derivatives
US3753981A (en) * 1970-07-15 1973-08-21 Squibb & Sons Inc 4-amino-2-styrylquinazoline compounds
FR2102221A1 (en) * 1970-08-12 1972-04-07 Squibb & Sons Inc 4-amino-(2-(5-nitro-2-furyl) vinyl)-quinazolines - antimicrobial gastrointestinal sterilisation agents
SU461621A1 (ru) * 1971-12-21 1975-11-25 Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе Способ получени замещенных 4-амино-2стирилхиназолинов
US3819628A (en) * 1972-07-31 1974-06-25 Sandoz Ag 2-phenyl-4-substituted amino-quinazolines and nitrates thereof
CH578556A5 (en) * 1973-02-20 1976-08-13 Sandoz Ag 2-(5-Nitro-heterocyclyl)-substd 4-amino-quinazolines - with bactericidal, trichomonacidal and amoebicidal activity
US3971783A (en) * 1973-03-07 1976-07-27 Pfizer Inc. 4-Aminoquinazoline derivatives as cardiac stimulants
US4055642A (en) * 1975-05-12 1977-10-25 Sandoz Ltd. Imidazolyl-2-quinazoline derivatives
FR2310756A1 (fr) * 1975-05-12 1976-12-10 Sandoz Sa Nouveaux derives de la quinazoline, leur preparation et leur application comme medicaments
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB2002746A (en) * 1977-06-17 1979-02-28 Gist Brocades Nv Copper complexes
US4269834A (en) * 1977-06-17 1981-05-26 Nauta Wijbe T Copper complexes of isoquinazolines
US4306065A (en) * 1979-12-19 1981-12-15 A. H. Robins Company, Incorporated 2-Aryl-4-substituted quinazolines
JPS58172379A (ja) * 1982-04-02 1983-10-11 Showa Denko Kk 新規なキナゾリン誘導体
EP0135975A2 (de) * 1983-09-29 1985-04-03 Akzo N.V. Chinazolin- und Isochinolin-Derivate
US4694000A (en) * 1983-09-29 1987-09-15 Akzo N.V. Quinazoline and isoquinoline derivatives
WO1989005297A1 (en) * 1987-12-03 1989-06-15 Smithkline Beckman Intercredit B.V. Compounds
US5047404A (en) * 1988-06-16 1991-09-10 Smith Kline & French Laboratories, Ltd. Chemical compounds
EP0371731A2 (de) * 1988-11-30 1990-06-06 Smith Kline & French Laboratories Limited Chinazolinon-Derivate
EP0395328A2 (de) * 1989-04-26 1990-10-31 Smith Kline & French Laboratories Limited Phenylpyrimidone Derivaten und ihre Anwendung als therapeutisches Mittel
WO1993007124A1 (en) * 1991-09-30 1993-04-15 Eisai Co., Ltd. Nitrogenous heterocyclic compound

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707998A (en) * 1993-03-31 1998-01-13 Eisai Co., Ltd. Nitrogen-containing fused-heterocycle compounds
US6300335B1 (en) * 1994-11-26 2001-10-09 Pfizer Inc. 4-aminoquinazoline derivative cGMP-PDE inhibitors for the treatment of erectile dysfunction
US20040087599A1 (en) * 1994-11-26 2004-05-06 Pfizer Inc cGMP-PDE inhibitors for the treatment of erectile dysfunction
USRE41065E1 (en) 1995-06-06 2009-12-29 Pfizer, Inc. Alkynl and azido-substituted 4-anilinoquinazolines
US6130223A (en) * 1996-10-24 2000-10-10 Merck Patent Gesellschaft Mit Beschrankter Haftung Thienopyrimidine with phosphodiesterase V inhibiting effect
WO1999032460A1 (de) * 1997-12-18 1999-07-01 Aventis Pharma Deutschland Gmbh Substituierte 2-aryl-4-amino-chinazoline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US6613772B1 (en) 1997-12-18 2003-09-02 Aventis Pharma Deutschland Gmbh Substituted 2-aryl-4-amino-chinazolines, method for the production and use thereof as medicaments
US20040214831A1 (en) * 1998-12-22 2004-10-28 Reto Naef cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction
US20070197560A1 (en) * 1998-12-22 2007-08-23 Reto Naef cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction
WO2000037061A2 (en) * 1998-12-22 2000-06-29 Novartis Ag cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION
WO2000037061A3 (en) * 1998-12-22 2000-10-26 Novartis Ag cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION
US20040063690A1 (en) * 1999-02-05 2004-04-01 Aventis Pharma Deutschland Gmbh Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them
US7045526B2 (en) * 1999-02-05 2006-05-16 Sanofi-Aventis Deutschland Gmbh Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them
SG121687A1 (en) * 1999-03-31 2006-05-26 Pfizer Prod Inc Processes and intermediates for preparing anti-cancer compounds
WO2001045641A3 (en) * 1999-11-30 2002-09-12 Parker Hughes Inst Inhibitors of thrombin induced platelet aggregation
US6635651B2 (en) 1999-11-30 2003-10-21 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
WO2001045641A2 (en) * 1999-11-30 2001-06-28 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
WO2001068615A1 (en) * 2000-03-13 2001-09-20 Chemrx Advanced Technologies, Inc. Quinazoline synthesis
US20040029900A1 (en) * 2000-06-29 2004-02-12 Rochus Jonas 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect
US7060823B2 (en) 2000-06-29 2006-06-13 Merck Patent Gmbh 5-aminoalkyl-pyrazolo[4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect
WO2002011707A2 (en) * 2000-08-08 2002-02-14 Nicox S.A. Drugs for incontinence
US20030203899A1 (en) * 2000-08-08 2003-10-30 Del Soldato Piero Drugs for incontinence
WO2002011707A3 (en) * 2000-08-08 2002-12-05 Nicox Sa Drugs for incontinence
US20050004110A1 (en) * 2000-09-15 2005-01-06 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
US7098330B2 (en) 2000-09-15 2006-08-29 Vertex Pharmaceuticals Incorporated Pyrazolylamine substituted quinazoline compounds useful as protein kinase inhibitors
US20040023990A1 (en) * 2000-11-25 2004-02-05 Hans-Michael Eggenweiler Use of pyrazolo[4,3-d]pyrimidines
WO2002043735A1 (en) * 2000-11-29 2002-06-06 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
US20070293667A1 (en) * 2001-09-17 2007-12-20 Werner Mederski 4-Amino-quinazolines
US20030105114A1 (en) * 2001-09-28 2003-06-05 Carpino Philip A. Methods of treatment and kits comprising a growth hormone secretagogue
US20030214965A1 (en) * 2002-03-13 2003-11-20 Liping Chen Method and apparatus for one directional communications in bidirectional communications channel
US20070161651A1 (en) * 2003-04-09 2007-07-12 Exelixis, Inc. Tie-2 modulators and methods of use
AU2004230928B2 (en) * 2003-04-09 2010-12-02 Exelixis, Inc. Tie-2 modulators and methods of use
WO2004092196A3 (en) * 2003-04-09 2005-03-17 Exelixis Inc Tie-2 modulators and methods of use
US7763627B2 (en) 2003-04-09 2010-07-27 Exelixis, Inc. Tie-2 modulators and methods of use
US7410975B2 (en) * 2003-06-20 2008-08-12 Coley Pharmaceutical Group, Inc. Small molecule toll-like receptor (TLR) antagonists
US20070232622A1 (en) * 2003-06-20 2007-10-04 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (TLR) antagonists
US20050119273A1 (en) * 2003-06-20 2005-06-02 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (TLR) antagonists
US7618975B2 (en) 2003-07-03 2009-11-17 Myriad Pharmaceuticals, Inc. 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20080039479A1 (en) * 2003-07-03 2008-02-14 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
US7989462B2 (en) 2003-07-03 2011-08-02 Myrexis, Inc. 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20070249601A1 (en) * 2003-07-03 2007-10-25 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
US20100069383A1 (en) * 2003-07-03 2010-03-18 Myriad Pharmaceuticals, Incorporated Compounds and therapeutical use thereof
US20070244113A1 (en) * 2003-07-03 2007-10-18 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
US20070208044A1 (en) * 2003-07-03 2007-09-06 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US20060258693A1 (en) * 2003-08-08 2006-11-16 Suzanne Chamberland Halogenated quinazolinyl nitrofurans as antibacterial agents
US20080146562A1 (en) * 2003-08-08 2008-06-19 Ulysses Pharmaceutical Products Inc., Halogenated quinazolinyl nitrofurans as antibacterial agents
US7410974B2 (en) 2003-08-08 2008-08-12 Ulysses Pharmaceutical Products, Inc. Halogenated Quinazolinyl nitrofurans as antibacterial agents
WO2005087227A1 (en) * 2004-03-04 2005-09-22 Neurogen Corporation Arylalkylamino-substituted quinazoline analogues
US20070219203A1 (en) * 2004-03-04 2007-09-20 Neurogen Corporation Arylalkylamino-substituted quinazoline analogues
US20080051398A1 (en) * 2005-01-03 2008-02-28 Myriad Genetics, Inc. Method of treating brain cancer
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP2286813A2 (de) 2006-01-31 2011-02-23 Novartis AG Verwendung von Naphthyridin-Derivaten als Heilmittel
US20100317659A1 (en) * 2009-02-27 2010-12-16 Sunny Abraham Jak kinase modulating compounds and methods of use thereof
US8349851B2 (en) 2009-02-27 2013-01-08 Ambit Biosciences Corp. JAK kinase modulating compounds and methods of use thereof
US8927711B2 (en) 2009-02-27 2015-01-06 Ambit Biosciences Corp. JAK kinase modulating compounds and methods of use thereof
US9308207B2 (en) 2009-02-27 2016-04-12 Ambit Biosciences Corp. JAK kinase modulating compounds and methods of use thereof
US20110190192A1 (en) * 2009-12-15 2011-08-04 Cebix Inc. Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
US8633207B2 (en) 2010-09-01 2014-01-21 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
US20130245052A1 (en) * 2010-11-26 2013-09-19 Hetero Research Foundation Novel polymorph of nilotinib hydrochloride
US8703788B2 (en) * 2010-11-26 2014-04-22 Bandi Parthasaradhi Reddy Polymorph of nilotinib hydrochloride
CN110291073A (zh) * 2016-12-13 2019-09-27 贝塔医疗私人有限公司 乙酰肝素酶抑制剂及其用途
CN113195470A (zh) * 2018-09-13 2021-07-30 南加州大学 作为治疗剂的新型单磷酸鸟苷合成酶抑制剂

Also Published As

Publication number Publication date
JP2657760B2 (ja) 1997-09-24
EP0579496B1 (de) 2001-11-14
JPH06192235A (ja) 1994-07-12
PT579496E (pt) 2002-05-31
DE69331122T2 (de) 2002-06-20
EP0579496A1 (de) 1994-01-19
KR940005613A (ko) 1994-03-21
DE69331122D1 (de) 2001-12-20
DK0579496T3 (da) 2002-02-25
JP2923742B2 (ja) 1999-07-26
CA2100626A1 (en) 1994-01-16
JPH0899962A (ja) 1996-04-16
ES2167325T3 (es) 2002-05-16
US5439895A (en) 1995-08-08
KR100191416B1 (ko) 1999-06-15
TW341566B (en) 1998-10-01
ATE208771T1 (de) 2001-11-15

Similar Documents

Publication Publication Date Title
US5436233A (en) 4-aminoquinazoline derivatives
US4728653A (en) 6-heteroaryl quinolone inotropic agents
US6114338A (en) Heterocyclic compounds
EP0379979B1 (de) Pyrazolopyridinverbindungen und Verfahren zu ihrer Herstellung
US6087368A (en) Quinazolinone inhibitors of cGMP phosphodiesterase
US4355040A (en) Hypotensive imidazole-5-acetic acid derivatives
US4288438A (en) Nitrogen-containing heterocyclic ring derivatives and analgesic and anti-inflammatory compositions and methods employing them
JP2006511583A (ja) マイトジェン活性化プロテインキナーゼ−活性化プロテインキナーゼ−２を阻害するための非環式ピラゾール化合物
JP2005532292A (ja) 新規化合物
US4572908A (en) Dihydropyridines
EP0888347A1 (de) Pharmazeutisch nutzliche verbindungen
US4782055A (en) Imidazopyridine compounds useful in the treatment of ulcers
US4847379A (en) 3,6-dihydro-1,5(2H)-pyrimidinecarboxylic acid esters
EP0208518B1 (de) 6-Phenyl-Pyridazin-Verbindungen
US5674886A (en) Triazolylated teritiary amine compound or salt thereof
US4740513A (en) Methyl substituted imidazol-1-yl quinolones
Bertinaria et al. Synthesis and anti‐Helicobacter pylori properties of NO‐donor/metronidazole hybrids and related compounds
EP0842933B1 (de) Neue naphthyridinderivate.
JPH02289548A (ja) ピリジン化合物
US6040309A (en) Benzothiophene derivatives useful in therapy
KR20010030683A (ko) 1,5-디페닐피라졸 유도체
EP0905133B1 (de) Tetrazolderivate als LTD4 und H1 Antagonisten
JPH10291988A (ja) 複素環式化合物
US4990507A (en) N-containing heterocyclic compounds, and composition comprising the same
JP3996657B2 (ja) 新規ナフチリジン誘導体

Legal Events

Date Code Title Description
AS Assignment

Owner name: ONO PHARMACEUTICAL CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEE, SUNG JAI;KONISHI, YOSHITAKA;MACINA, OREST TARAS;AND OTHERS;REEL/FRAME:006880/0482;SIGNING DATES FROM 19931215 TO 19931220

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20070725